RL
69
-4
IFF
47
-4
WAT
48
-11
BDX
56
10
AA
56
15
WMB
68
2
DNB
74
-6
EXPD
43
-4
EL
15
-3
IR
63
-3
HPE
44
-2
HAL
48
-3
CPB
22
-5
BK
74
3
ESS
62
-3
VMC
53
-4
ICE
59
-3
AIV
64
4
AME
74
-4
DVN
14
-6
RL
69
-4
IFF
47
-4
WAT
48
-11
BDX
56
10
AA
56
15
WMB
68
2
DNB
74
-6
EXPD
43
-4
EL
15
-3
IR
63
-3
HPE
44
-2
HAL
48
-3
CPB
22
-5
BK
74
3
ESS
62
-3
VMC
53
-4
ICE
59
-3
AIV
64
4
AME
74
-4
DVN
14
-6
Financhill
Back

SELLAS Life Sciences Group Quote, Financials, Valuation and Earnings

Trump wins! Dow to 75,000? Details here

See the explosive "Document 20" details here.
Sell
45

SLS
SELLAS Life Sciences Group

Last Price:
1.32
Seasonality Move:
7.89%

7 Day Trial

ALL ACCESS PASS

$ 7

Trump's "Document 20" Revealed: Smart Americans Could Get Rich During His 2nd Term

See if stocks could soar as much as 1,000% if history repeats itself.

SELLAS Life Sciences Group Price Quote

$1.32

SELLAS Life Sciences Group Key Stats

Sell
45
SELLAS Life Sciences Group (SLS) is a Sell
Day range:
$1.25 - $1.35
52-week range:
$0.50 - $1.72
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
28.05%
Volume:
845K
Avg. volume:
697.6K
1-year change:
36.08%
Market cap:
$81.7M
Revenue:
$0
EPS:
$-0.92

How Much Does SELLAS Life Sciences Group Make?

Data Unavailable

Is SELLAS Life Sciences Group Growing As A Company?

Data Unavailable

SELLAS Life Sciences Group Stock Price Performance

What Is SELLAS Life Sciences Group 52-Week High & Low?

SELLAS Life Sciences Group Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy SELLAS Life Sciences Group?

Is SELLAS Life Sciences Group Cash Flow Positive?

  • What Is SLS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$32.2M
  • What Is SELLAS Life Sciences Group’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $30.5M
  • What Is SELLAS Life Sciences Group’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $0

SELLAS Life Sciences Group Return On Invested Capital

Data Unavailable

SELLAS Life Sciences Group Earnings Date & Stock Price

SELLAS Life Sciences Group Competitors

SELLAS Life Sciences Group Dividend Yield

SELLAS Life Sciences Group Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 21.06%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 5.83
Upside from Last Price: 341.92%

Major Shareholders

  • How many SLS shares are owned by institutional investors?
    6.9M SLS shares are owned by institutional investors
  • How many SLS shares are owned by insiders?
    2.4M SLS shares are owned by insiders